Sharon Chung, MD, MAS, discusses specific recommendations for the treatment and management of ANCA-associated vasculitis from the latest ACR Guideline.
Search results for: "Michael Putman"
Vasculitis Guidelines in Focus, Part 1: The Guideline Project
Sharon A. Chung, MD, MAS, director of the vasculitis clinic at the University of California, San Francisco, served as the principal investigator of the overall vasculitis guideline effort and talks about the process here.
RheumMadness: An Educational Tournament
RheumMadness is an online collaborative learning experience created to educate trainees, rheumatologists and the wider medical community about recent advances and important concepts in rheumatology. The project is funded by the Rheumatology Research Foundation Clinician Scholar Educator (CSE) Award and modeled after NephMadness, an educational initiative of the American Journal of Kidney Diseases (AJKD) that…
Thank You to Our 2020 Authors
The editors of The Rheumatologist would like to thank all of the rheumatologists, rheumatology professionals and professional writers who took the time and effort in an unprecedented pandemic year to ensure we could continue to bring you the important clinical guidelines, case reports, current research, COVID-19 coverage and so much more. This publication would not…
Rheumatology in the Age of COVID-19: HCQ Shortages Driven by Small, Nonrandomized Study
No data exist for prescribing hydroxychloroquine for post-exposure prophylaxis, and we should not prescribe it for this indication.
New ACR/ARP Committee Members Are Ready to Work
Volunteering is a great way to give back and can be truly meaningful. Myriad worthwhile causes exist, so it can be hard to choose among them, but donating time to ACR and ARP committees helps promote rheumatology practice and brings awareness to rheumatic diseases. The College relies on volunteers to help achieve strategic priorities, promote…
FDA Approves Nintedanib for SSc-ILD, But Temper Your Expectations
The U.S. Food & Drug AdminÂistration (FDA) approved nintedanib for systemic sclerosis associated interstitial lung disease (SSc-ILD) on Sept. 6 after a randomized, controlled trial (SENSCIS) demonstrated significant benefit against placebo.1 At a cost of $96,000 per year, treatment reduced the adjusted annual rate of change in forced vital capacity (FVC) from –93.3 mL in…
For Residents, Mystery Patients Often Require Rheumatologist Advice
As a first-year internal medicine resident, I find myself consulting rheumatologists for just about every mystery patient in our hospital. Like many residents, I was initially intimidated by the complexity of this elusive field. At first glance, diagnosis and management seem completely inaccessible to a first-year resident. But several rheumatology consults later, I can confidently…